Indications
Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days. Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.
Composition
- Active substance
- granisetron
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Sancuso
- Active substance
- granisetron
- ATC code
- A04AA02
- Therapeutic area
- Vomiting, Cancer
- Marketing authorisation holder
- Grünenthal GmbH
- Status